Ignite Creation Date:
2024-05-06 @ 8:21 AM
Last Modification Date:
2024-10-26 @ 11:59 AM
Study NCT ID:
NCT02729025
Status:
COMPLETED
Last Update Posted:
2022-09-23
First Post:
2016-03-08
Brief Title:
Effects of Proprotein Convertase SubtilisinKexin Type 9 PCSK9 Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoproteina Lpa
Sponsor:
Amgen
Organization:
Amgen
Study Overview
Official Title:
A RaNdomized Double-blInd Placebo ConTrolled Study Characterizing THe Effects of PCSK9 Inhibition On Arterial Wall Inflammation in Patients With Elevated Lpa ANITSCHKOW
Status:
COMPLETED
Status Verified Date:
2022-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ANITSCHKOW
Brief Summary:
A study to assess the effects of proprotein convertase subtilisin kexin type 9 PCSK9 inhibition on the arterial wall inflammation in patients with elevated lipoproteina
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2015-003731-35 | EUDRACT_NUMBER | None | None |